Klinikum Aschaffenburg-Alzenau gGmbH
- Address
- lock Available on a paid plan
Hematologic Malignancies
The department of Haematologie und Onkologie at Klinikum Aschaffenburg-Alzenau focuses on blood‑related cancers such as acute myeloid leukemia, myelodysplastic syndrome and related high‑risk subtypes, aiming to improve survival and reduce disease progression.
- Testing targeted inhibitors for IDH1/IDH2 mutations
- Comparing FLT3 inhibitors to standard therapy
- Assessing venetoclax‑based regimens for event‑free survival
- Evaluating maintenance strategies after intensive chemotherapy
With eight investigators overseeing five active trials, the site contributes valuable data on novel treatment combinations for patients with newly diagnosed disease.
Advanced Breast Cancer
Researchers are studying patients with advanced HER2‑negative, hormone‑receptor‑positive breast cancer in the first‑line setting, exploring how molecular patterns influence response to therapies such as ribociclib.
- Analyzing spatial and temporal biomarkers of drug efficacy
- Identifying mechanisms of resistance to CDK4/6 inhibition
- Integrating molecular profiling to personalize treatment
The comprehensive approach seeks to refine therapeutic decisions and enhance outcomes for women facing this challenging disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 53 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Aschaffenburg-Alzenau gGmbH
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 53 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fulvestrant | 4 | Unknown | 2022-10-13 | 2025-12-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.